Xyrem
(sodium oxybate)ApprovedSmall molecule
Jazz PharmaceuticalsSodium oxybate is used to treat narcolepsy, a condition where people fall asleep suddenly and unexpectedly during the day, and it also helps reduce muscle weakness episodes that can occur with this condition.[2] Xyrem is currently approved and in use across 22 indications[4].[1]
Xyrem is one of 306 small molecule programs targeting Spasmodic Dystonia. It is currently in Approved.
22
Indications
29
Total Trials
2
Active Trials
305
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 20 indications
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Xyrem
Jazz PharmaceuticalsApproved
Celexa
AbbViePreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Inversine
TTargacept Inc.
Preclinical
Catapres
Boehringer IngelheimPreclinical
Vivarin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Fatigue Syndrome3 trials
Tremor3 trials
Sleep2 trials
Safety and Efficacy1 trial
19 more indications
Efficacy1 trial
Alternating Hemiplegia of Childhood1 trial
Parkinson's Disease1 trial
Essential Tremor1 trial
Concentration1 trial
Hypersomnia1 trial
Sedation1 trial
Sodium Oxybate Versus Midazolam for Comfort Sedation
Completed·—·Phase 4·NCT05085873·22 enrolled
TIA1 trial
Alcohol Withdrawal1 trial
Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome
Completed·—·Phase 4·NCT02090504·127 enrolled
Alzheimer's Disease1 trial
Excessive Daytime Sleepiness1 trial
Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)
Completed·—·Phase 2·NCT00641186·30 enrolled
Insomnia1 trial
REM sleep behavior disorder1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Xyrem drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for sodium oxybate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- GABA-B Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company